Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms
- 23 June 2006
- Vol. 24, S106-S113
- https://doi.org/10.1016/j.vaccine.2006.05.110
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trialThe Lancet, 2006
- Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial NeoplasiaObstetrics & Gynecology, 2006
- Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomavirusesInternational Journal of Cancer, 2005
- Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialThe Lancet, 2004
- Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex AssayClinical and Vaccine Immunology, 2003
- Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particlesVaccine, 2001
- Safety and Immunogenicity Trial in Adult Volunteers of a Human Papillomavirus 16 L1 Virus-Like Particle VaccineJNCI Journal of the National Cancer Institute, 2001
- The serological response to papillomavirusesSeminars in Cancer Biology, 1999
- Prospective study on the development of antibodies against human papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infectionJournal of Medical Virology, 1995
- IMMUNIZATION OF RABBITS TO INFECTIOUS PAPILLOMATOSISThe Journal of Experimental Medicine, 1937